News

Article

J&J COVID-19 Vaccinations to Resume in the US

The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts within approximately one to two weeks following vaccination.

Johnson & Johnson announced on April 23, 2021 that vaccinations with its single-shot COVID-19 vaccine will resume for all adults aged 18 years and older in the US following a decision from United States Centers for Disease Control (CDC) and FDA.

The decision comes from the US CDC Advisory Committee on Immunization Practices following the evaluation of data showing a rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) within approximately one to two weeks following vaccination, Johnson & Johnson said in a company press release. The company has updated the vaccine’s emergency use authorization fact sheets for vaccination providers, recipients, and caregivers to include information about the diagnosis and treatment of thrombosis with thrombocytopenia.

“As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere,” said Paul Stoffels, chief scientific officer of Johnson & Johnson. “We will collaborate with health authorities around the world to educate healthcare professionals and the public to ensure this very rare event can be identified early and treated effectively.”

Source: Johnson & Johnson

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More